Genomic signature of BRCA1 deficiency in sporadic basal‐like breast tumors

About 10–20% of all breast carcinomas show a basal‐like phenotype, while ∼ 90% of breast tumors from BRCA1‐mutation carriers are of this subtype. There is growing evidence that BRCA1‐mutated tumors are not just a specific subset of the basal‐like tumors, but that (the majority of) basal‐like tumors show a dysfunctional BRCA1 pathway. This has major treatment implications, because emerging regimens specifically targeting DNA repair mechanisms would then be most effective against these tumors. To further understand the involvement of BRCA1 deficiency in sporadic basal‐like tumors, we investigated 41 basal‐like tumors for BRCA1 mRNA expression by quantitative real‐time polymerase chain reaction, BRCA1 promoter methylation, their genomic profile by array‐CGH, and gene expression levels by whole genome expression arrays. Array‐CGH results were compared to those of 34 proven BRCA1‐mutated tumors. Basal‐like tumors were subdivided into two equal groups: deficient and proficient in BRCA1 gene expression. The chromosomal makeup of BRCA1 deficient sporadic basal‐like tumors was similar to that of BRCA1‐mutated tumors. BRCA1 proficient sporadic basal‐like tumors were more similar to nonbasal‐like tumors. Only half of the basal‐like breast tumors are actually deficient in BRCA1 expression. Gain of chromosome arm 3q is a marker for BRCA1 deficiency in hereditary and sporadic breast tumors. © 2010 Wiley‐Liss, Inc.

[1]  Qing-yuan Zhang,et al.  Basal-like breast cancer , 2012 .

[2]  P. Devilee,et al.  Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH , 2012, Breast Cancer Research and Treatment.

[3]  R. Bracci,et al.  BRCA1 expression in triple negative sporadic breast cancers. , 2010, Analytical and quantitative cytology and histology.

[4]  Yuntao Xie,et al.  BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer , 2009, Cancer science.

[5]  S. Linn,et al.  Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. , 2009, European journal of cancer.

[6]  O. Johannsson,et al.  Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes , 2009, Breast Cancer Research.

[7]  P. Nederlof,et al.  High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. , 2009, Cancer research.

[8]  Stephanie A Cohen,et al.  The prevalence of BRCA1 mutations among young women with triple-negative breast cancer , 2009, BMC Cancer.

[9]  W. Barry,et al.  CpG Island Tumor Suppressor Promoter Methylation in Non-BRCA-Associated Early Mammary Carcinogenesis , 2009, Cancer Epidemiology Biomarkers & Prevention.

[10]  A. Vincent-Salomon,et al.  High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. , 2009, Cancer research.

[11]  M. Fackler,et al.  Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J. Peterse,et al.  Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH , 2008, Breast Cancer Research and Treatment.

[13]  J. Benítez,et al.  An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes. , 2008, Carcinogenesis.

[14]  Ian O Ellis,et al.  Basal-like breast cancer: a critical review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Tutt,et al.  Triple negative tumours: a critical review , 2007, Histopathology.

[16]  S. Tavaré,et al.  High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer , 2007, Genome Biology.

[17]  Harry Bartelink,et al.  Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas , 2007, Breast Cancer Research.

[18]  P. Neven,et al.  Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Vincent-Salomon,et al.  Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity , 2007, Breast Cancer Research.

[20]  A. Ashworth,et al.  BRCA1 dysfunction in sporadic basal-like breast cancer , 2007, Oncogene.

[21]  P. Nederlof,et al.  Automated array-CGH optimized for archival formalin-fixed, paraffin-embedded tumor material , 2007, BMC Cancer.

[22]  P. Johnston,et al.  BRCA1, a potential predictive biomarker in the treatment of breast cancer. , 2007, The oncologist.

[23]  Robert Tibshirani,et al.  Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer , 2006, Genes, chromosomes & cancer.

[24]  J. Reis-Filho,et al.  Basal-like breast cancer and the BRCA1 phenotype , 2006, Oncogene.

[25]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[26]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[27]  P. Nederlof,et al.  A multiplex PCR predictor for aCGH success of FFPE samples , 2005, British Journal of Cancer.

[28]  Sunil R Lakhani,et al.  The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. , 2005, Pathology, research and practice.

[29]  Tara L. Naylor,et al.  Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. , 2005, Cancer research.

[30]  G. Ball,et al.  High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.

[31]  R. Tibshirani,et al.  A tail strength measure for assessing the overall univariate significance in a dataset. , 2005, Biostatistics.

[32]  Julian Peto,et al.  Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.

[33]  Franck Picard,et al.  A statistical approach for array CGH data analysis , 2005, BMC Bioinformatics.

[34]  Peter Devilee,et al.  Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. , 2005, Cancer research.

[35]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[36]  William D. Foulkes,et al.  Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .

[37]  L. Bégin,et al.  Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.

[38]  M. O’Reilly,et al.  DNA damage induces downregulation of histone gene expression through the G1 checkpoint pathway , 2004, The EMBO journal.

[39]  L. Yakubov,et al.  Extracellular genomic DNA protects mice against radiation and chemical mutagens , 2003, Genome Biology.

[40]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[41]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Marcel J T Reinders,et al.  Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. , 2002, Cancer research.

[43]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[45]  N. Pavlidis,et al.  Cancer of Unknown Primary Origin. , 1997, The oncologist.

[46]  J Isola,et al.  Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. , 1997, Cancer research.

[47]  A. Shamsuddin,et al.  Fecal mutagen fecapentaene-12 damages mammalian colon epithelial DNA. , 1987, Carcinogenesis.

[48]  Lodewyk F. A. Wessels,et al.  Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response , 2009, Breast Cancer Research and Treatment.

[49]  P. Neven,et al.  Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer : BIG 198 , 2007 .

[50]  B Asselain,et al.  Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems. , 1998, Anticancer research.

[51]  B J Williams,et al.  Comparative genomic hybridization. , 1996, Methods in molecular medicine.